Pharma News

Researchers at NYU Grossman School of Medicine and Janssen Biotech Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus—a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

Cancer drugs that stimulate the body’s immune system to attack tumors are a promising way to treat many types of cancer. However, some of these drugs produce too much systemic inflammation when delivered intravenously, making them harmful to use in patients.

Scientists in Melbourne have designed a new type of oral capsule that could mean pain-free delivery of insulin and other protein drugs. Co-lead researcher Professor Charlotte Conn, a biophysical chemist from RMIT University, said protein drugs had proven challenging to deliver orally as the drugs degrade very quickly in the stomach – until now.

Gamida Cell Ltd a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv), for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer - one of the most aggressive and difficult to treat cancers - by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice.

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.

The All India Organisation of Chemists & Druggists (AIOCD) has written to the Drug Controller General of India (DCGI) on operations of online Pharmacies. AIOCD stated that despite the issuance of notices, E-Pharmacy companies have not stopped their operations.

Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.).

Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the U.S. Sanofi has simultaneously entered into a direct royalty agreement with Sobi to share a portion of U.S. net sales from nirsevimab.

Lupin Limited announced the launch of its new state-of-the-art Regional Reference Laboratory in Bengaluru, Karnataka, as part of the expansion of its diagnostics network. The new laboratory marks a significant step forward in Lupin Diagnostics' mission to provide accessible and affordable diagnostics and preventive healthcare services across India. The Regional Reference Laboratory complements the company's existing network of 25 laboratories and 410+ collection centers across India.